Literature DB >> 18199773

The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.

Maria-Magdalena Mocanu1, Astrid Nissen, Katrin Eckermann, Inna Khlistunova, Jacek Biernat, Dagmar Drexler, Olga Petrova, Kai Schönig, Hermann Bujard, Eckhard Mandelkow, Lepu Zhou, Gabriele Rune, Eva-Maria Mandelkow.   

Abstract

We describe two new transgenic mouse lines for studying pathological changes of Tau protein related to Alzheimer's disease. They are based on the regulatable expression of the four-repeat domain of human Tau carrying the FTDP17 (frontotemporal dementia and parkinsonism linked to chromosome 17) mutation deltaK280 (Tau(RD)/deltaK280), or the deltaK280 plus two proline mutations in the hexapeptide motifs (Tau(RD)/deltaK280/I277P/I308P). The deltaK280 mutation accelerates aggregation ("proaggregation mutant"), whereas the proline mutations inhibit Tau aggregation in vitro and in cell models ("antiaggregation mutant"). The inducible transgene expression was driven by the forebrain-specific CaMKIIalpha (calcium/calmodulin-dependent protein kinase IIalpha) promoter. The proaggregation mutant leads to Tau aggregates and tangles as early as 2-3 months after gene expression, even at low expression (70% of endogenous mouse Tau). The antiaggregation mutant does not aggregate even after 22 months of gene expression. Both mutants show missorting of Tau in the somatodendritic compartment and hyperphosphorylation in the repeat domain [KXGS motifs, targets of the kinase MARK (microtubule affinity regulating kinase)]. This indicates that these changes are related to Tau expression rather than aggregation. The proaggregation mutant causes astrogliosis, loss of synapses and neurons from 5 months of gene expression onward, arguing that Tau toxicity is related to aggregation. Remarkably, the human proaggregation mutant Tau(RD) coaggregates with mouse Tau, coupled with missorting and hyperphosphorylation at multiple sites. When expression of proaggregation Tau(RD) is switched off, soluble and aggregated exogenous Tau(RD) disappears within 1.5 months. However, tangles of mouse Tau, hyperphosphorylation, and missorting remain, suggesting an extended lifetime of aggregated wild-type Tau once a pathological conformation and aggregation is induced by a proaggregation Tau species.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199773      PMCID: PMC6670355          DOI: 10.1523/JNEUROSCI.2824-07.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  109 in total

1.  Regulation of tau pathology by the microglial fractalkine receptor.

Authors:  Kiran Bhaskar; Megan Konerth; Olga N Kokiko-Cochran; Astrid Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Neuron       Date:  2010-10-06       Impact factor: 17.173

Review 2.  Are tangles as toxic as they look?

Authors:  Tara L Spires-Jones; Katherine J Kopeikina; Robert M Koffie; Alix de Calignon; Bradley T Hyman
Journal:  J Mol Neurosci       Date:  2011-06-03       Impact factor: 3.444

3.  Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

Authors:  Donna M Barten; Patrizia Fanara; Cathy Andorfer; Nina Hoque; P Y Anne Wong; Kristofor H Husted; Gregory W Cadelina; Lynn B Decarr; Ling Yang; Victoria Liu; Chancy Fessler; Joan Protassio; Timothy Riff; Holly Turner; Christopher G Janus; Sethu Sankaranarayanan; Craig Polson; Jere E Meredith; Gemma Gray; Amanda Hanna; Richard E Olson; Soong-Hoon Kim; Gregory D Vite; Francis Y Lee; Charles F Albright
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

Review 4.  Amyloid structure and assembly: insights from scanning transmission electron microscopy.

Authors:  Claire Goldsbury; Ulrich Baxa; Martha N Simon; Alasdair C Steven; Andreas Engel; Joseph S Wall; Ueli Aebi; Shirley A Müller
Journal:  J Struct Biol       Date:  2010-09-22       Impact factor: 2.867

Review 5.  Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.

Authors:  Narendran Annadurai; Khushboo Agrawal; Petr Džubák; Marián Hajdúch; Viswanath Das
Journal:  Cell Mol Life Sci       Date:  2017-06-20       Impact factor: 9.261

Review 6.  Dendritic vulnerability in neurodegenerative disease: insights from analyses of cortical pyramidal neurons in transgenic mouse models.

Authors:  Jennifer I Luebke; Christina M Weaver; Anne B Rocher; Alfredo Rodriguez; Johanna L Crimins; Dara L Dickstein; Susan L Wearne; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2010-02-24       Impact factor: 3.270

7.  Truncation of tau at E391 promotes early pathologic changes in transgenic mice.

Authors:  Pamela J McMillan; Brian C Kraemer; Linda Robinson; James B Leverenz; Murray Raskind; Gerard Schellenberg
Journal:  J Neuropathol Exp Neurol       Date:  2011-11       Impact factor: 3.685

8.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

9.  Caspase activation precedes and leads to tangles.

Authors:  Alix de Calignon; Leora M Fox; Rose Pitstick; George A Carlson; Brian J Bacskai; Tara L Spires-Jones; Bradley T Hyman
Journal:  Nature       Date:  2010-03-31       Impact factor: 49.962

10.  Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease.

Authors:  Jennifer B Paulson; Martin Ramsden; Colleen Forster; Mathew A Sherman; Eileen McGowan; Karen H Ashe
Journal:  Am J Pathol       Date:  2008-07-31       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.